Releases - Karo Bio

View:
 

Found press releases

 

Annual Report 2011

5/22/2012 8:00 AM EST
Stockholm, May 22, 2012 – Karo Bio AB’s annual report for 2011 is as of today available on the company’s website www.karobio.com.
The printed version of the annual report will be distributed to shareholders and others specifically subscribing to the printed version. It can also be ordered from Karo Bio by mail to Karo Bio AB, attn: Eva Kruse, Novum, 141 57 Huddinge, Sweden, by fax to +46 8 774 8261, or by...

NOTICE OF ANNUAL GENERAL MEETING OF KARO BIO AB (PUBL)

5/11/2012 5:30 AM EST
Stockholm, May 11, 2012 - The shareholders of Karo Bio AB (publ) are hereby given notice to attend the annual general meeting on June 12th, 2012, at 4.00 pm CET at Hörsalen, Novum Forskningspark (level 4 – elevator E), Hälsovägen 7, Huddinge, Sweden.
Right to participate
A right to participate at the annual general meeting applies for those who have been recorded in the share register kept by Euroclear Sweden...

EXTRAORDINARY GENERAL MEETING IN KARO BIO

4/27/2012 11:00 AM EST
STOCKHOLM, April 27, 2012 – Karo Bio AB (publ). At the Extraordinary General Meeting in Karo Bio the following resolutions were made.

1. The General Meeting resolved to approve the Board’s proposal that the company shall not enter into liquidation.

2. Resolution regarding amendment of the Articles of Association

2a The limits for the share capital
The General Meeting resolved that the §4 of the Articles of...

INTERIM REPORT JANUARY - MARCH 2012

4/27/2012 2:30 AM EST
The January–March 2012 period in brief

· Net sales amounted to MSEK 8.3 (0.0)
· Net loss was MSEK 54.0 (47.7)
· Loss per share was SEK 0.14 (0.12)
· Cash flow from operating activities was MSEK -41.6 (-47.5)
· Cash and cash equivalents and other short-term investments totaled MSEK 117.0 (312.1) at the end of the period, which is deemed to suffice to finance operations for more than 12 months
· Closure costs...

COLLABORATION WITH ZYDUS CADILA EXPIRES – KARO BIO CONTINUES TO DEVELOP SAFER GL...

4/2/2012 2:30 AM EST
STOCKHOLM, 2 April 2012 – Karo Bio AB (publ) and the Indian pharmaceutical company Zydus Cadila have decided not to further extend their joint glucocorticoid receptor research and development program. Karo Bio focuses its continued development towards a previously not described mechanism of glucocorticoid regulation.
In early 2008, Karo Bio and Zydus Cadila initiated a collaboration to discover and develop...

CHANGED DATE FOR THE ANNUAL GENERAL MEETING AND NOTICE TO EXTRAORDINARY GENERAL ...

3/23/2012 3:30 AM EST
According to the previous press release of 14 February 2012, Karo Bio has discontinued the clinical phase III-project with the lipid-lowering drug eprotirome and decided to terminate the project. The decision changes the conditions for the company’s continued direction. In order to give the Board of Directors and the executive management the opportunity for a new planning and renewed description of the business, the...

KARO BIO LAYS OFF 16 EMPLOYEES

2/21/2012 4:00 AM EST
STOCKHOLM, February 21, 2012 – Karo Bio AB (publ) completes notice of redundancy issued in November and lays off 16 employees. As previously announced, the purpose of this downsizing is to reduce costs.

Together with other personnel changes in 2011, this reduction in personnel will result in annual savings of approx. MSEK 17. The savings will take effect gradually in 2012.

 

For further information, please...

KARO BIO TERMINATES THE EPROTIROME PROGRAM

2/14/2012 2:42 AM EST
STOCKHOLM, February 14, 2012 - Karo Bio AB (publ) has decided to discontinue the development program for eprotirome after an animal study has demonstrated unwanted effects following long-term exposure. The planned spin-off of the preclinical part of operations will not proceed.
The animal study is a toxicology study in which damage to cartilage was seen in dogs that were given eprotirome for up to 12 months....

Information regarding trading suspension

2/13/2012 2:31 AM EST
STOCKHOLM, 13 February 2012 - Karo Bio AB (publ) estimates to provide information on Tuesday morning related to the Stockholm Stock Exchange's decision to suspend trading in its shares.

About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas...

INTERIM REPORT JANUARY - DECEMBER 2011

2/8/2012 2:30 AM EST
The January–December period and the fourth quarter 2011 in brief

· Net sales amounted to MSEK 0.0 (0.0)
· Net loss was MSEK 226.6 (163.5), whereof the fourth quarter MSEK 50.6 (50.1)
· Loss per share was SEK 0.59 (0.67), whereof the fourth quarter SEK 0.13 (0.20)
· Cash flow from operating activities was MSEK -198.3 (-158.9), whereof the fourth quarter MSEK -37.9 (-44.3). The increase in the full year primarily...

Karo Bio

The mission of Karo Bio is to develop novel pharmaceuticals for treatment of metabolic diseases. The company is in an exciting stage of its development and is transforming from a drug discovery company to a company with ...

View more


  CONTACT  
  • Erika Söderberg Johnson
  • +46 8 608 60 00
  •